Comparison of Vitamin D, Calcium, Parathyroid Hormone (PTH) and Osteocalcin changes in Breast Cancer Patients and Normal People

Breast cancer is the most common malignancy worldwide and the second cause of cancer death in women. Previous studies have shown that vitamin D has anti_proliferative and anticancer effects on tumor cells. Changes in serum levels of calcium and parathyroid hormone (PTH) have also been observed in many types of cancer. Furthermore, osteocalcin is known as a sensitive biomarker for prognosis of breast cancer and detection of bone metastasis. This study aimed to evaluate the prediagnostic levels of vitamin D, calcium, PTH and osteocalcin in breast cancer patients and compare them with normal people to achieve early detection and prevention of future cancer progression. Methodology: This study concluded ۳۵ female breast cancer patients and ۳۵ healthy participants as controls. The average age of both groups was exactly the same (۳۴, ۴۷ years). Blood samples of patients with breast cancer were taken from the tumor bank of Imam Khomeini Hospital, after pathological confirmation and based on the inclusion criteria. Blood samples from all patients and controls were centrifuged at ۳۰۰۰ rpm for ۱۵ minutes and stored at -۲۰ degrees. Serum concentrations of vitamin D, calcium, PTH and osteocalcin were measured using quantitative luminescence and ELISA methods. Data were analyzed through SPSS software, using appropriate statistical tests. A significance level of ۰.۰۵ was considered. Result: Experiments on the expression of estrogen and progesterone receptors have shown that the receptors of these two hormones are almost identical in breast cancer patients. The statistical significance level at P<۰.۰۵ was set. There was no statistically significant difference between the serum calcium and vitamin D levels of breast cancer patients and the control group (P<۰.۰۵). Serum vitamin D concentrations in patients with positive PR and ER receptors showed no statistically significant difference compared to patients with negative PR and ER receptors (P<۰.۰۵). Serum PTH and osteocalcin concentrations were both significantly higher in the breast cancer group (P<۰.۰۱). Conclusion: Serum vitamin D and calcium concentrations in breast cancer patients did not show statistically significant differences compared with normal subjects. Expression of PR and ER receptors also showed no significant association with calcium and vitamin D concentrations. Furthermore, serum PTH and osteocalcin levels were significantly increased in breast cancer patients. These results may contribute to cancer prognosis, prevention and development of new treatments. However, large-scale clinical studies and investigations with a larger number of patients are needed to understand the relationship and impact of these variables on breast cancer progression.

کلیدواژه ها:

breast cancer ، vitamin D ، calcium ، parathyroid hormone ، Osteocalcin